Berkeley News


Covenant Winery Summer Music Series Announces July Calendar Berkeley, CA Drinks District is Hopping

BERKELEY, Calif., July 6, 2022 (SEND2PRESS NEWSWIRE) — The Covenant Winery Summer Music Series, which kicked off on Memorial Day weekend in Berkeley at their Sixth Street winery, continues through July with four concerts, July 3, 10, 17 and 24, 2022. Showcased at the winery’s new outdoor tasting lounge, fans of wine and music can enjoy the vibe of the Berkeley Drinks District, while sipping a nice array of California and Israeli wines.

Covenant Winery Summer Concert Series Debuts Memorial Day Weekend – Monday May 30

BERKELEY, Calif., May 10, 2022 (SEND2PRESS NEWSWIRE) — The Covenant Winery Summer Concert Series kicks off Memorial Day weekend in Berkeley with acclaimed French/American jazz pianist, composer and arranger Franck Amsallem. Franck has recorded ten CDs under his own name as well as a collaboration, “New York Stories,” with (Berkeley’s own) Joshua Redman, Roy Hargrove, and Danny Gatton on Blue Note.

Share International Announces Campaign to End All War

BERKELEY, Calif., March 24, 2022 (SEND2PRESS NEWSWIRE) — Share International USA, a non-profit educational organization, announced today the start of a daily prayer/meditation vigil designed to engage the power of the people to bring peace in the current Russia/Ukraine conflict as well as all others ongoing worldwide.

Ethical Traveler Announces 2021’s ‘Ten Best (Post-Pandemic) Destinations’ Awards

BERKELEY, Calif., Feb. 16, 2021 (SEND2PRESS NEWSWIRE) — Every year, California-based Ethical Traveler reviews the world’s developing nations for their commitment to human rights, social welfare, and environmental protection. The ten destinations with the most impressive records are honored with Ethical Destinations Awards.

Flightpath Biosciences Launches via Illumina Accelerator to Conduct Largest Clinical Biomarker Study in Lyme Disease

BERKELEY, Calif., Feb. 9, 2021 (SEND2PRESS NEWSWIRE) — Flightpath Biosciences, a life sciences company, launched today claiming a spot in Illumina Accelerator’s second global class to develop diagnostics and microbiome-targeted therapeutics to treat rare pathogen-driven diseases. The company has operated in stealth since its founding in mid-2019 and has built a pipeline of drug candidates for a wide range of diseases, starting with acute and Persistent Lyme Disease (PLD).